Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
Nuvectis Pharma (NASDAQ: NVCT) will participate in the H.C. Wainwright 2nd BioConnect Investor Conference.
CEO Ron Bentsur will present on May 20, 2024, at 12:00 PM Eastern Time at NASDAQ headquarters in NYC.
As a clinical-stage biopharmaceutical company, Nuvectis focuses on developing precision medicines for serious oncology conditions with unmet medical needs.
- Participation in a high-profile investor conference increases visibility.
- CEO Ron Bentsur's presentation could attract potential investors.
- Focus on developing precision medicines for serious oncology conditions addresses significant medical needs.
- No new clinical data or financial updates provided in the announcement.
- Lack of details about any new partnerships or advancements in their pipeline.
Fort Lee, NJ, May 16, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright 2nd BioConnect Investor Conference at the NASDAQ world headquarters in New York City.
| Event | H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ |
| Date | May 20th, 2024 |
| Time | 12:00 PM Eastern Time |
| Link | Fireside Chat [Link] |
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. The U.S. Food and Drug Administration granted Fast Track Designation to the NXP800 development program in platinum resistant, ARID1a-mutated ovarian carcinoma, and Orphan Drug Designation for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 has a unique mechanism of action in that it inhibits both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study.
Company Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
201-614-3151
rbentsur@nuvectis.com
Media Relations Contact
Christopher M. Calabrese
LifeSci Advisors
Tel: 917-680-5608
ccalabrese@lifesciadvisors.com
FAQ
What event will Nuvectis Pharma participate in on May 20, 2024?
What time is the Nuvectis Pharma presentation at the H.C. Wainwright BioConnect Investor Conference?
Where will the H.C. Wainwright 2nd BioConnect Investor Conference take place?
Who will present on behalf of Nuvectis Pharma at the H.C. Wainwright BioConnect Investor Conference?
What is the focus of Nuvectis Pharma's development efforts?
What is the stock symbol for Nuvectis Pharma?
